These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7495077)

  • 1. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of seminal factor IX and factor IXa in fertile, nonfertile, and vasectomy subjects: a step closer toward identifying a functional clotting system in human semen.
    Lwaleed BA; Greenfield RS; Hicks J; Birch BR; Cooper AJ
    J Androl; 2005; 26(1):146-52. PubMed ID: 15611579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes.
    Kusch M; Seitz R; König H
    Thromb Haemost; 1998 Apr; 79(4):778-83. PubMed ID: 9569192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo models of thrombogenic potential: usefulness and limitations.
    MacGregor I; McLaughlin L; Drummond O; Prowse C; Ferguson J
    Acta Haematol; 1995; 94 Suppl 1():18-23; discussion 24. PubMed ID: 7571990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombogenicity of factor IX concentrates: in vitro and in vivo (rabbit) studies.
    Cash JD; Owens R; Dalton RG; Prescott RJ
    Vox Sang; 1978; 35(1-2):105-10. PubMed ID: 664565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
    Gray E; Walker D; Heath A; Barrowcliffe TW
    Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombogenicity of prothrombin complex concentrates].
    Dornheim G; Klöcking HP; Wulkow R; Storch H; Töpfer G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):571-9. PubMed ID: 1714862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion.
    Aronson DL; Thomas DP
    Thromb Haemost; 1985 Dec; 54(4):866-70. PubMed ID: 3879019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombogenicity of factor IX complex: in vivo investigation.
    Aronson DL; Menache D
    Dev Biol Stand; 1987; 67():149-55. PubMed ID: 3609475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
    Smith KJ
    Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.
    Yu Y; Millar CM
    J Thromb Haemost; 2014 Jan; 12(1):62-70. PubMed ID: 24215160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.